The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

被引：90

作者：

Collins, P. ^{[1
]}

Chalmers, E. ^{[2
]}

Chowdary, P. ^{[3
]}

Keeling, D. ^{[4
]}

Mathias, M. ^{[5
]}

O'Donnell, J. ^{[6
]}

Pasi, K. J. ^{[7
]}

Rangarajan, S. ^{[8
]}

Thomas, A. ^{[9
]}

机构：

[1] Univ Wales Hosp, Arthur Bloom Haemophilia Ctr, Cardiff, S Glam, Wales

[2] Royal Hosp Sick Children, Haemophilia Ctr, Glasgow, Lanark, Scotland

[3] Royal Free Hosp, Katharine Dormandy Haemophilia Ctr, London, England

[4] Churchill Hosp, Haemophilia Ctr, Oxford, England

[5] Great Ormond St Hosp Sick Children, Haemophilia Ctr, London, England

[6] St James Hosp, Haemophilia Ctr, Dublin, Ireland

[7] Royal London Hosp, Haemophilia Ctr, London, England

[8] Basingstoke & North Hampshire Hosp, Haemophilia Ctr, Basingstoke, Hants, England

[9] Royal Infirm Edinburgh NHS Trust, Haemophilia Ctr, Edinburgh, Midlothian, Scotland

来源：

HAEMOPHILIA | 2016年 / 22卷 / 04期

关键词：

coagulation factor concentrates; enhanced half-life; pharmacokinetics; prophylaxis; FC FUSION PROTEIN; RECOMBINANT FACTOR-IX; SEVERE HEMOPHILIA-A; GLYCOPEGYLATED FACTOR-IX; ALBUMIN RIX-FP; FACTOR-VIII; B PATIENTS; PROLONGED ACTIVITY; PHARMACOKINETIC PROPERTIES; PROPHYLACTIC TREATMENT;

D O I：

10.1111/hae.13013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Enhanced half-life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children. This guidance document is a consensus statement from the UK Haemophilia Centres Doctors' Organisation and aims to give pragmatic advice on the use of these products in routine practice.

引用

页码：487 / 498

页数：12

共 50 条

[1] Bjorkman S, 2013, J Thromb Haemost, V11, P180
[2] Boggio LN, 2014, BLOOD, P1526
[3] Switching from current factor VIII (FVIII) to longer acting FVIII concentrates - what is the real potential benefit?
Carcao, M.
[J]. HAEMOPHILIA, 2015, 21 (03) : 297 - 299
[4] Carcao M, 2015, HAEMOPHILIA, V21, P28
[5] Chowdary P, 2015, BLOOD, P2283
[6] Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
Collins, P. W.
Fischer, K.
Morfini, M.
Blanchette, V. S.
Bjorkman, S.
[J]. HAEMOPHILIA, 2011, 17 (01) : 2 - 10
[7] Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
Collins, P. W.
Blanchette, V. S.
Fischer, K.
Bjorkman, S.
Oh, M.
Fritsch, S.
Schroth, P.
Spotts, G.
Astermark, J.
Ewenstein, B.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) : 413 - 420
[8] Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Collins, Peter W.
Young, Guy
Knobe, Karin
Karim, Faraizah Abdul
Angchaisuksiri, Pantep
Banner, Claus
Gursel, Turkiz
Mahlangu, Johnny
Matsushita, Tadashi
Mauser-Bunschoten, Eveline P.
Oldenburg, Johannes
Walsh, Christopher E.
Negrier, Claude
[J]. BLOOD, 2014, 124 (26) : 3880 - 3886
[9] Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)
Collins, Peter W.
Chalmers, Elizabeth
Hart, Daniel P.
Liesner, Ri
Rangarajan, Savita
Talks, Kate
Williams, Mike
Hay, Charles R.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (02) : 153 - 170
[10] Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
Coyle, T. E.
Reding, M. T.
Lin, J. C.
Michaels, L. A.
Shah, A.
Powell, J.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (04) : 488 - 496

← 1 2 3 4 5 →